What is the 13F Pro Quality Score for FEMY?

13F Pro ranks FEMASYS INC (FEMY) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View FEMY's current score at https://13fpro.ai/company/FEMY (free sign-up required for the full ranking).

Where does 13F Pro source FEMY data?

All FEMASYS INC fundamentals and ownership data come directly from SEC EDGAR. FEMASYS INC files with the SEC under CIK 1339005. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is FEMY in?

FEMASYS INC (FEMY) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is FEMY research updated on 13F Pro?

FEMY's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

FEMASYS INC(FEMY)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1339005 FEMY stock profile & AI dashboard →

13F Pro Quality Score

31.4/100

Rank #2,455 of 2,962 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why FEMY Scores 31/100

exact factor attribution · 2026-09-11

FEMY's composite is driven by revenue growth and earnings growth, held back by scale and free cash flow. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Revenue growth

+8.4 pts

92th pct

Earnings growth

+2.2 pts

95th pct

Institutional flow

+2.1 pts

92th pct

Shareholder dilution

-2.0 pts

10th pct

Capital efficiency

-4.5 pts

5th pct

Earnings quality

-4.6 pts

4th pct

Profitability

-6.4 pts

7th pct

Free cash flow

-6.8 pts

5th pct

Scale

-7.0 pts

4th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

Unusual Activity in FEMY

Events flagged as statistical outliers against FEMY's own multi-year baseline — not fixed dollar thresholds.

Insider cluster2026-08-07
5 insiders bought $134,000 of FEMY in 30 days — 10.0σ above this company's 2-year norm
View source filing →

FEMY Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for FEMASYS INC (FEMY), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores FEMY at 31.4/100 on a 32-signal composite quality model, placing it at rank #2,455 of 2,962 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), FEMASYS INC reports quarterly revenue of $331.8K, net income of $-4.5M, free cash flow of $-3.9M. Top institutional holders of FEMY by reported 13-F value include Dauntless Investment Group, VANGUARD CAPITAL MANAGEMENT, JANE STREET GROUP, based on the most recent SEC filings. FEMY trades on the Nasdaq exchange and files with the SEC under CIK 1339005. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate FEMY daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for FEMASYS INC directly from SEC EDGAR. FEMASYS INC's 13F Pro composite quality score has ranged between 26 and 31 since 2026, currently 31.4 — an improving long-term trajectory across 9 quarterly and live scoring snapshots.

✦

Fun facts about FEMASYS INC

Quirks, history, and lore behind FEMY — the kind of stuff that makes a stock memorable.

1
The Basics
A small-cap U.S. medical device company · listed on Nasdaq · focused on women's health procedures.
2
The Numbers
Revenue in the single-digit millions annually — this is a pre-profitability, clinical-stage device maker burning cash while chasing FDA clearances.
3
The History
Founded in the early 2000s and headquartered in Atlanta, Georgia, it has spent years developing minimally invasive tools for gynecological procedures.
4
The Secret
Its pipeline targets two significant unmet needs: permanent birth control and fertility assessment — both delivered through a transcervical, no-incision approach.
5
The Lore
The company's lead device, FemBloc, aims to replace surgical tubal ligation with an in-office procedure — no operating room, no general anesthesia, no scalpel.
6
The Giveaway
Its ticker spells out a very close approximation of its own name, and its entire mission is building a transcervical platform for women who never want to see the inside of an OR again.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q2 2026

$331.8K

Net Income

Q2 2026

$-4.5M

Free Cash Flow

Q2 2026

$-3.9M

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+40.8% YoY

$2.3MFY 2025

FY22 $1.2MFY23 $1.1MFY24 $1.6MFY25 $2.3M

Net Income

+1.0% YoY

$-18.6MFY 2025

FY22 $-11.4MFY23 $-14.2MFY24 $-18.8MFY25 $-18.6M

Operating Income

+1.1% YoY

$-17.6MFY 2025

FY22 $-11.6MFY23 $-14.5MFY24 $-17.8MFY25 $-17.6M

EPS (Diluted)

+44.7% YoY

$-0.47FY 2025

FY22 $-0.96FY23 $-0.93FY24 $-0.85FY25 $-0.47

Total Assets

+66.5% YoY

$20.7MFY 2025

FY22 $16.9MFY23 $27.8MFY24 $12.4MFY25 $20.7M

Op. Cash Flow

+3.9% YoY

$-18.7MFY 2025

FY22 $-10.7MFY23 $-11.3MFY24 $-19.4MFY25 $-18.7M

Free Cash Flow

+4.9% YoY

$-19.2MFY 2025

FY22 $-11.1MFY23 $-11.4MFY24 $-20.2MFY25 $-19.2M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$2.3M +40.8%	$1.6M +52.0%	$1.1M -11.1%	$1.2M +2.2%	$1.2M +13.7%	$1.0M
Net Income	$-18.6M +1.0%	$-18.8M -32.1%	$-14.2M -25.0%	$-11.4M -51.2%	$-7.5M -9.0%	$-6.9M
Operating Income	$-17.6M +1.1%	$-17.8M -22.6%	$-14.5M -25.1%	$-11.6M -39.1%	$-8.3M -20.2%	$-6.9M
EPS (Diluted)	$-0.47 +44.7%	$-0.85 +8.6%	$-0.93 +3.1%	$-0.96 +14.3%	$-1.12 +84.4%	$-7.20
Total Assets	$20.7M +66.5%	$12.4M -55.2%	$27.8M +64.3%	$16.9M -40.9%	$28.6M +275.7%	$7.6M
Operating Cash Flow	$-18.7M +3.9%	$-19.4M -72.4%	$-11.3M -5.1%	$-10.7M -35.3%	$-7.9M -60.8%	$-4.9M
Free Cash Flow	$-19.2M +4.9%	$-20.2M -76.9%	$-11.4M -2.6%	$-11.1M -35.2%	$-8.2M -66.7%	$-4.9M

Get alerted when FEMY's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for FEMASYS INC including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of FEMY

Dauntless Investment Group, LLC
$7.8M1,867,987 sh
VANGUARD CAPITAL MANAGEMENT LLC
$260.1K62,232 sh
JANE STREET GROUP, LLC
$219.5K52,511 sh
GEODE CAPITAL MANAGEMENT, LLC
$129.3K30,920 sh
UBS Group AG
$78.5K18,777 sh
CITADEL ADVISORS LLC
$70.7K16,921 sh
VANGUARD FIDUCIARY TRUST CO
$52.2K12,492 sh
OSAIC HOLDINGS, INC.
$10.0K2,397 sh
BlackRock, Inc.
$7.5K1,784 sh
NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO
$4.2K1,000 sh

Fund	Value	Shares
Dauntless Investment Group, LLC	$7.8M	1,867,987
VANGUARD CAPITAL MANAGEMENT LLC	$260.1K	62,232
JANE STREET GROUP, LLC	$219.5K	52,511
GEODE CAPITAL MANAGEMENT, LLC	$129.3K	30,920
UBS Group AG	$78.5K	18,777
CITADEL ADVISORS LLC	$70.7K	16,921
VANGUARD FIDUCIARY TRUST CO	$52.2K	12,492
OSAIC HOLDINGS, INC.	$10.0K	2,397
BlackRock, Inc.	$7.5K	1,784
NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO	$4.2K	1,000

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put FEMY on your watchlist

Track score changes the day FEMASYS INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is FEMY a good stock to buy?

13F Pro's AI-powered analysis of FEMASYS INC (FEMY) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for FEMY are available on the FEMY stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. FEMY is classified as a small company.

Which hedge funds own FEMY?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling FEMY. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of FEMASYS INC's investment landscape.